Neoadjuvant Dual vs Single Checkpoint Inhibitors in High-Risk Melanoma
1. The pathological response rate had an OR of 3.16 when comparing neoadjuvant dual vs single checkpoint inhibitors. 2. The...
Though associated with rising costs, the majority of publicly-funded cancer medications included in Ontario, Canada are those with substantial survival benefit
1. Roughly 65% of the cancer medication budget is allocated to treatments that provide improvement in survival 2. Immune checkpoint...
Neoadjuvant Chemoimmunotherapy for Lung Cancer – A Meta-Analysis
1. The overall survival had a significant hazard ratio (0.65) when comparing neoadjuvant chemoimmunotherapy to neoadjuvant chemotherapy. 2. Both groups...
Pazopanib does not improve disease-free survival post-metastasectomy for renal cell carcinoma patients
1. Pazopanib did not improve disease-free survival in post-metastasectomy renal cell carcinoma patients 2. There was a concerning trend favouring...
Immunotherapy vs Chemoimmunotherapy in Older Adults With Advanced NSCLC
1. Adding chemotherapy to immunotherapy did not prolong OS or PFS, with non-significant differences in HR. 2. Grade 3 or...
A cell-free, blood-based DNA screening test for colorectal cancer compared to colonoscopy
1. 83.1% of patients with confirmed colorectal cancer had a positive cfDNA test meeting the accepted standard as outlined by...
Venetoclax monotherapy effectively treats relapsed or refractory chronic lymphocytic leukemia
1. VENICE-1 observed high response rates (complete or partial remission) in both BCRi-naïve and BCRi-pretreated patients with refractory or relapsed...
Adding ribociclib to endocrine therapy appears to improve invasive disease-free survival in patients with early breast cancer
1. Invasive disease-free survival was significantly higher in patients receiving adjuvant ribociclib + NSAI when compared to patients receiving NSAI...
Tabelecleucel is a therapeutic option for EBV-related post-transplant lymphoproliferative disease
1. Tabelecleucel provided clinical improvement in patients with EBV-related post-transplant lymphoproliferative disease. 2. There were no fatal treatment related adverse...
Enobosarm in AR-positive, ER-positive, and HER2-Negative Advanced Breast Cancer
1. The clinical benefit rate was 32% in the 9 mg group and 29% in the 18 mg group. 2....
